source
- Q32 Bio’s alopecia drug bempikibart meets Phase 2 goal, driving shares up 80%Q32 Bio reported that its experimental alopecia areata therapy, bempikibart, achieved the primary endpoint in the second part of a Phase 2 trial. Two‑fifths of participants grew enough hair to cove…
- Digital health funding jumps to $7.4 billion in first half of 2026Digital health startups secured $7.4 billion in venture capital during the first six months of 2026, according to research firm Rock Health. This represents a $1 billion increase compared with the…